IE 11 is not supported. For an optimal experience visit our site on another browser.

Cumberland Pharmaceuticals Inc. is Today's Focus Stock on MicroStockProfit.com

DALLAS, Jan. 18, 2011 (GLOBE NEWSWIRE) -- MicroStockProfit.com announces an investment report featuring Cumberland Pharmaceuticals Inc. (Nasdaq:CPIX). The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.
/ Source: GlobeNewswire

DALLAS, Jan. 18, 2011 (GLOBE NEWSWIRE) -- MicroStockProfit.com announces an investment report featuring Cumberland Pharmaceuticals Inc. (Nasdaq:CPIX). The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

The full report is available at:

Cumberland Pharmaceuticals Inc. (CPIX) is a specialty pharmaceutical company focused on the acquisition, development and commercialization of branded prescription products. Its primary target markets include hospital acute care and gastroenterology. The Company's product portfolio includes Acetadote (acetylcysteine) Injection for the treatment of acetaminophen poisoning, Caldolor (ibuprofen) injection, the first injectable treatment for pain and fever available in the United States, and Kristalose (lactulose) for Oral Solution, a prescription laxative. CPIX markets and sells its products through its dedicated hospital and gastroenterology sales forces in the United States, which together comprised 113 sales representatives and managers as of March 1, 2010, and work to partner its products to reach international markets.

For only $19 a month, you can sign up for our real-time stock alert service. Click here to join now:

In the report, the analyst notes:

"CPIX said last week that U.S. regulators had approved a new formulation of its drug Acetadote, a treatment for acetaminophen poisoning. The drug is indicated to prevent or lessen liver injury in patients who have ingested a potentially hepatotoxic quantity of acetaminophen, common ingredient in many over-the-counter painkillers.

"Following the approval, the Company plans to launch the product immediately and discontinue selling the older formulation, which has been available since 2004."

To read the entire report visit:

See what investors are saying about CPIX at

Get breaking news on CPIX at

MicroStockProfit.com is a small-cap research and investment commentary provider. MicroStockProfit.com strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on MicroStockProfit please visit:

MicroStockProfit.com Disclosure

MicroStockProfit.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. MicroStockProfit.com is a Web site wholly owned by BlueWave Advisors, LLC. Neither MicroStockProfit.com nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. Please read our report and visit our Web site, MicroStockProfit.com, for complete risks and disclosures.

CONTACT: Brian Johnson info@microstockprofit.com 1-888-307-2850